Related Experiment Video
Updated: Dec 21, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Cisplatin Changes Expression of SEMA3B in Endometrial Cancer
Wojciech Peszek1, Piotr Kras1, Beniamin O Grabarek2,3
1Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialized Hospital, Kraków, Poland
Background:
Semaphorin 3B (SEMA3B) is characterized as a strong suppressing factor of the proliferation of cancerous cells and also by its anti-angiogenic effect. However, the knowledge on the changes in the expression profile of SEMA3B under the influence of cisplatin in endometrial cancer remains fragmented. The aim of this work was to note the changes in expression of SEMA3B when under the influence of cisplatin in the endometrial cancer cell line.
Methods:
Ishikawa cell line cells were exposed to three different concentrations of cisplatin: 2.5μM; 5μM; 10μM for 12, 24 and 48 hours and were compared to cells untreated by the drug. Changes in the expression profile of SEMA3B were determined based upon RtqPCR (mRNA) alongside the ELISA assay (protein). The Statistica 13.0 PL program was used for statistical analysis (p<0.05).
Results:
Changes on the transcriptome level seem to be more dynamic than on the proteome level. Regardless of the concentration given or the exposition period, the expression of semaphorin 3B was, in fact, higher in cells exposed to cisplatin. Statistically substantial differences (p<0.05) in the expression of SEMA3B mRNA and protein were seen for all incubation periods at the given cisplatin level when compared to the control.
Conclusion:
Cisplatin causes a growth in the expression of SEMA3B in an endometrial cancer cell culture, this results in the restoration in the state of cell homeostasis and shows the effectiveness of pharmacotherapy, including a low risk of drug resistance.
Insights
Cisplatin treatment increases Semaphorin 3B (SEMA3B) expression in endometrial cancer cells. This finding suggests SEMA3B
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Semaphorin 3B (SEMA3B) exhibits anti-cancer properties, inhibiting proliferation and angiogenesis.
- The effect of cisplatin on SEMA3B expression in endometrial cancer is not well understood.
Purpose of the Study:
- To investigate the impact of cisplatin on SEMA3B expression in an endometrial cancer cell line.
Main Methods:
- Ishikawa endometrial cancer cells were treated with varying cisplatin concentrations (2.5, 5, 10μM) for 12, 24, and 48 hours.
- SEMA3B expression was analyzed at both mRNA (RtqPCR) and protein (ELISA) levels.
- Statistical analysis was performed using Statistica 13.0 PL (p<0.05).
Main Results:
- Cisplatin exposure led to increased SEMA3B expression at both mRNA and protein levels compared to untreated controls.
- Transcriptome-level changes were more dynamic than proteome-level changes.
- Statistically significant differences in SEMA3B expression were observed across all incubation periods and cisplatin concentrations.
Conclusions:
- Cisplatin significantly upregulates SEMA3B expression in endometrial cancer cells.
- This upregulation may contribute to restoring cellular homeostasis.
- The findings support the therapeutic potential of cisplatin and suggest a low risk of drug resistance.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
01:06Induced Pluripotent Stem Cells
Somatic...